| Literature DB >> 32432078 |
Abstract
Amyloid fibril formation is a hallmark of diverse neurodegenerative and metabolic diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), and type 2 diabetes mellitus (T2DM). Conventional diagnosis is based on the appearance of fibrils or plaques, while neglects the role of early-stage oligomers in the disease progression. Recent studies have uncovered that it is the early-stage oligomer, rather than the mature fibril, that greatly contributes cytotoxicity. The formation of oligomers involves complicate structural conversions and it is essential to investigate their conformational changes for a better understanding of aggregation mechanism. The coexistence of soluble early-stage oligomers, intermediates, and pre-fibril species makes it difficult to be differentiate by morphological methods, and only average structural information is provided as they lack the ability of separation. Therefore, mass spectrometry (MS) becomes an alternative technique that presents new and complementary insights into the onset of amyloid fibrils. This review highlights the hotspots and important achievements by MS in the field of amyloid formation mechanism, including the direct detection and differentiation of soluble oligomers (native MS), unambiguous identification of interacted sites involved in the onset of aggregation [hydrogen/deuterium exchange (HDX) and chemical cross-linking (CX)], and conformational switch that leads to fibrilization [collision cross section (CCS) regularity by ion mobility (IM)].Entities:
Keywords: aggregation mechanism; amyloid fibril; conformational analysis; early-stage oligomers; mass spectrometry
Year: 2020 PMID: 32432078 PMCID: PMC7215083 DOI: 10.3389/fchem.2020.00324
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
Representative studies done by mass spectrometry (MS)-based techniques for early-stage oligomer analysis.
| Aβ1−42 | Native top-down | Interaction between Aβ1−42 and metal ion | Lermyte et al., |
| NNQQNY | ESI-IM-MS | Mechanism of peptide assembly | Bleiholder et al., |
| hIAPP | ESI-IM-MS | Mechanisms and binding patterns of small molecule inhibitors | Young et al., |
| PrP | HDX-MS | Amyloid fibril formation mechanism | Singh and Udgaonkar, |
| β2m | HDX-MS | Mechanism of Cu(II) induced amyloid formation | Borotto et al., |
| Aβ1−42 | FPOP-MS | Conformational change of the aggregation process | Li et al., |
| Sup 35 | CX-MS | Mechanism of different folding patterns | Wong and King, |
| α-crystallin | CX-MS | Mechanism of αA66-80 peptide induced aggregation | Kannan et al., |
A.
Figure 1Experimental cross section (Å2) as a function of oligomer size (n). (A) NVVVVY shows an early transition at n = 4; β-sheet structures are observed from n = 4 to 7. Structures with steric zipper cross sections are detected at n = 6, 7, and 8. (B) NNVVNY shows transitions to steric zipper and β-sheet; isotropic cross sections are observed up to n = 12 and primarily β-sheet structures for n > 12. (C) NVVQIY shows a transition to β-sheet at n = 10, and β-sheet structures are also at n = 19; steric zipper formation also likely appears between n = 4 and 11. (D) NVQVVY shows a transition from n = 7 to 10, with β-sheet structures being observed up to n = 14. (E) NNVVNV shows isotropic cross section up to n = 10 with no β-sheet oligomers and only one steric zipper at n = 9. (F) VIQVVY shows isotropic cross sections up to n = 8 and no larger oligomers. Modified with permission from Do et al. (2013), Copyright 2013 American Chemical Society.